Abstract
Cyslabdan produced by Streptomyces sp. K04-0144 was found to potentiate imipenem activity against methicillin-resistant Staphylococcus aureus (MRSA). The MIC value of imipenem against MRSA was reduced from 16 to 0.015 microg/ml in combination with cyslabdan. Study on anti-MRSA activity of other typical antibiotics in combination with cyslabdan showed that the potentiating activity was limited to beta-lactam antibiotics. Furthermore, among beta-lactam antibiotics, the activity of carbapenems was most remarkably potentiated by cyslabdan.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acetylcysteine / administration & dosage
-
Acetylcysteine / analogs & derivatives*
-
Acetylcysteine / metabolism
-
Acetylcysteine / pharmacology
-
Anti-Bacterial Agents / administration & dosage*
-
Anti-Bacterial Agents / biosynthesis
-
Anti-Bacterial Agents / pharmacology*
-
Carbapenems / administration & dosage
-
Diterpenes / administration & dosage*
-
Diterpenes / metabolism
-
Diterpenes / pharmacology*
-
Drug Synergism
-
Humans
-
Imipenem / administration & dosage*
-
Methicillin Resistance
-
Microbial Sensitivity Tests
-
Molecular Structure
-
Staphylococcus aureus / drug effects*
-
Staphylococcus aureus / isolation & purification
-
Streptomyces / metabolism*
-
beta-Lactams / administration & dosage
Substances
-
Anti-Bacterial Agents
-
Carbapenems
-
Diterpenes
-
beta-Lactams
-
cyslabdan
-
Imipenem
-
Acetylcysteine